Next Article in Journal
Risks and Function of Breast Cancer Susceptibility Alleles
Next Article in Special Issue
Hodgkin Lymphoma in People Living with HIV
Previous Article in Journal
Antagonists of Growth Hormone-Releasing Hormone Inhibit the Growth of Pituitary Adenoma Cells by Hampering Oncogenic Pathways and Promoting Apoptotic Signaling
Previous Article in Special Issue
Review of Treatment Options for the Management of Advanced Stage Hodgkin Lymphoma

FDG-PET/CT for the Management of Post-Chemotherapy Residual Mass in Hodgkin lymphoma

Research and Clinical Innovation Department, Antoine Lacassagne Cancer Centre, 06189 Nice, France
Haematology and Bone Marrow Transplantation Department, Medical University of Gdansk, 80-214 Gdansk, Poland
Author to whom correspondence should be addressed.
Academic Editor: Theodoros Vassilakopoulos
Cancers 2021, 13(16), 3952;
Received: 22 June 2021 / Revised: 21 July 2021 / Accepted: 2 August 2021 / Published: 5 August 2021
(This article belongs to the Special Issue Hodgkin Lymphoma)
In the present review the authors report the predictive value of FDG/PET-CT (PET) on treatment outcome of Hodgkin lymphoma patients showing a post-chemotherapy residual mass, based on the published reports of PET-guided consolidation radiotherapy after different-intensity chemotherapy regimens such as ABVD or BEACOPPescalated. A special focus will be dedicated to the role of PET for assessing patients with a residual mass during and after immunotherapy with immune checkpoint inhibitors. Finally, the interpretation criteria of PET will be also reviewed, and the role of alternative imaging techniques discussed.
In the present review, the authors report the published evidence on the use of functional imaging with FDG-PET/CT in assessing the final response to treatment in Hodgkin lymphoma. Despite a very high overall Negative Predictive Value of post-chemotherapy PET on treatment outcome ranging from 94% to 86%, according to different treatment intensity, the Positive Predicting Value proved much lower (40–25%). In the present review the Authors discuss the role of PET to guide consolidation RT over a RM after different chemotherapy regimens, both in early and in advanced-stage disease. A particular emphasis is dedicated to the peculiar issue of the qualitative versus semi-quantitative methods for End-of Therapy PET scan interpretation. A short hint will be given on the role of FDG-PET to assess the treatment outcome after immune checkpoint inhibitors. View Full-Text
Keywords: Hodgkin lymphoma; residual mass; PET Hodgkin lymphoma; residual mass; PET
Show Figures

Graphical abstract

MDPI and ACS Style

Gallamini, A.; Kurlapski, M.; Zaucha, J.M. FDG-PET/CT for the Management of Post-Chemotherapy Residual Mass in Hodgkin lymphoma. Cancers 2021, 13, 3952.

AMA Style

Gallamini A, Kurlapski M, Zaucha JM. FDG-PET/CT for the Management of Post-Chemotherapy Residual Mass in Hodgkin lymphoma. Cancers. 2021; 13(16):3952.

Chicago/Turabian Style

Gallamini, Andrea, Michał Kurlapski, and Jan M. Zaucha. 2021. "FDG-PET/CT for the Management of Post-Chemotherapy Residual Mass in Hodgkin lymphoma" Cancers 13, no. 16: 3952.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop